<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224964</url>
  </required_header>
  <id_info>
    <org_study_id>Biomarker sputum airway study3</org_study_id>
    <nct_id>NCT01224964</nct_id>
  </id_info>
  <brief_title>Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3</brief_title>
  <acronym>BioSput-Air</acronym>
  <official_title>Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of the study are:

      1. To unravel the importance of molecular phenotyping in predicting the response to classical
      anti-asthma treatment (leukotriene antagonists)

      The investigators have developed a non-invasive technique based on mRNA analysis of induced
      sputum that enables us to study airway inflammation in detail. This technique forms the basis
      for our current project based on the following hypotheses:

        1. Different molecular asthma phenotypes exist: a Th2 phenotype and a non Th2 phenotype as
           reported by Woodruff and colleagues (Woodruff PG et al). Sputum mRNA cytokine levels can
           be used to diagnose Th2 asthma and discriminate this from non-Th2 asthma.

        2. Based on our previous research and preliminary data that non-Th2 asthma can be further
           divided in Th17 asthma and Th1+Th2 asthma; besides these, a fourth group without Th2,
           Th17 or Th1 characteristics also exist.

        3. These subgroups have different responses to anti-leukotrienes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A lot of patients recruited in our center were already on montelukast treatment. It was not
    possible to recruit sufficient patients for the study.
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sputum cytokine mRNA</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>responsiveness to the medication</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Asthmatic Patients</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>long-acting beta2-mimetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Montelukast, 10 mg</description>
    <arm_group_label>Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>long acting beta2 mimetic</intervention_name>
    <description>ICS+long acting beta2 agonist: twice daily</description>
    <arm_group_label>long-acting beta2-mimetic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  uncontrolled persistent asthmatics on daily inhaled corticosteroids (GINA)

        Exclusion Criteria:

          -  viral/fungal/bacterial infection +fever (&lt;1 month)

          -  asthma exacerbation (&lt;3 months)

          -  other respiratory disease (CF, ciliary dyskinesia,bronchiectasis)

          -  cardiac patients using beta-blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique MA Bullens, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lab of clinical immunology, O&amp;N I Herestraat 49 - bus 811, 3000 Leuven, België</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven F Seys, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Lab of clinical immunology, O&amp;N I Herestraat 49 - bus 811, 3000 Leuven, België</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>October 22, 2014</last_update_submitted>
  <last_update_submitted_qc>October 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Dominque Bullens</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

